Core Insights - Jianfan Bio's case study has been included in the "Business for Good Case Collection 2025," highlighting its commitment to social responsibility and innovation in the medical technology sector [1] - The case focuses on over 20 years of "responsibility evolution," emphasizing the company's efforts to break foreign medical technology monopolies through independent innovation in blood purification technology [1] - The initiative includes innovations in payment systems, enhancing grassroots medical capabilities, and promoting industry collaboration to make technology more accessible [1] Company Initiatives - Jianfan Bio initiated the "919 Uremia Care Day" to build social consensus and create a closed loop of "original innovation - technology accessibility - social advocacy" [1] - The company exemplifies how a domestic enterprise in the medical technology field can empower social welfare through core technology, fulfilling the dual mission of "treating diseases and saving lives" while contributing to industrial growth [1] Event Details - The forum where the case study was presented was guided by the China Association for International Exchange of Personnel and organized by the Hainan Asia Public Welfare Research Institute along with several other institutions [1] - The event attracted over 600 participants from 16 countries and regions, including government representatives, international organization leaders, philanthropists, entrepreneurs, and scholars, to discuss Asian public welfare development [1] - The live broadcast of the forum garnered over 900,000 views, indicating significant interest in global sustainable development challenges [1]

在乙肝领域，特宝生物支持的"珠峰项目"为无数患者带来了临床治愈的希望；在儿科领域，益佩生®同 样承载着这样的使命——让更多矮小症患儿不仅能"用得起"长效生长激素，更能"用得好、用得安全"。 此次益佩生®纳入医保，将显著提升药物的可及性，降低患者家庭经济负担，让高品质创新药"飞入寻 常百姓家"。而企业对高标准、无防腐剂等生产工艺的坚守，则确保了药品在可及性提升的同时，始终 保持安全可靠的品质和疗效。这种"可及性"与"高质量"的统一，正是特宝生物"以患者为中心"承诺的最 佳注脚。 展望2026年，随着新版医保目录的落地执行，益佩生®有望继派格宾®之后，成为驱动特宝生物业绩增 长的第二引擎。而对于资本市场而言，一家始终将技术创新聚焦于解决实际临床问题的公司，其长期成 长逻辑已然清晰可见。 此次进入医保，对于特宝生物而言意义深远，不仅标志着产品获得国家级市场准入资格，更在医保谈 判"保基本"的大背景下，验证了一个核心商业命题：具备显著临床优势和更高安全性的差异化创新药， 才能获得认可与支持。 益佩生®能够顺利入局，得益于其扎实的"品质硬实力"，尤其是其在分子设计层面的突破性创新和安全 性升级，为产品构建了难以复制的差 ...

Core Insights - The successful negotiation for the inclusion of Teabo Bio's long-acting growth hormone, Yipei Growth Hormone Injection, into the medical insurance directory marks a significant milestone for the company, indicating national market access and validating the importance of differentiated innovative drugs with clinical advantages and higher safety [1][2] Group 1: Product Development and Innovation - Yipei Growth Hormone's entry into the insurance directory is attributed to its strong "quality hard power," particularly breakthroughs in molecular design and safety upgrades, creating a unique competitive advantage [1] - Teabo Bio has focused on high-barrier biotechnological advancements, translating them into clinical benefits that address user pain points, exemplified by its journey from Hepatitis B treatment to pediatric growth support [1] Group 2: Market Impact and Accessibility - The inclusion of Yipei Growth Hormone in the insurance directory is expected to enhance drug accessibility, reduce the economic burden on families of affected children, and ensure that high-quality innovative drugs are available to the general public [2] - The company's commitment to high standards and preservative-free production processes ensures that increased accessibility does not compromise the safety and efficacy of the drug, aligning with its patient-centered approach [2] Group 3: Future Growth Potential - Looking ahead to 2026, Yipei Growth Hormone is anticipated to become a second growth engine for Teabo Bio, following the success of its Hepatitis B treatment, indicating a clear long-term growth trajectory for the company in the capital market [2]

Core Viewpoint - The establishment of the Donghu Center by Changjiang Industrial Group in Wuhan marks a new phase of cluster synergy and ecological empowerment for listed companies [1] Group 1: Donghu Center and Its Role - The Donghu Center serves as a headquarters base for listed companies rooted in Wuhan and acts as a value hub linking capital, technology, and markets [1] - The center is positioned as a strategic support point for the central China region, aiming to radiate nationwide [1] - The group plans to use the Donghu Center to build an innovation ecosystem, integrate various resources, and invest in the real economy, creating a demonstration area that combines scenic innovation and vibrant ecology [1] Group 2: Changjiang Industrial Group Overview - Changjiang Industrial Group is a provincial-level industrial investment platform in Hubei, responsible for strategic emerging industry investment and management of provincial industrial investment funds [2] - The group operates under a model that includes one investment platform per industry, multiple enterprise entities, a fund group, and a public service system [2] - The focus is on eight major industrial sectors: optoelectronic information, automotive and high-end manufacturing, life health, modern chemicals, new energy, ecological environment, new materials, and Beidou digital [2]

Core Viewpoint - The third A+ Aquatic Feed Summit focuses on addressing the industry's reliance on high-protein feeds, which leads to increased costs and environmental pressures, promoting a shift towards precision, efficiency, and eco-friendly practices in aquaculture [1][2] Group 1: Industry Challenges - The aquaculture feed industry is facing significant issues related to high-protein competition, leading to increased raw material consumption and negative impacts on water quality and fish metabolism [1] - The low protein retention rate and conversion efficiency in the industry indicate substantial room for improvement [1] Group 2: Company Solutions - The company proposes a "Three Highs and Three Lows" technical strategy, focusing on high quality, health, and growth while reducing protein, loss, and feed ratio [1] - The "Four Guarantees" product quality system aims to enhance growth speed by 10%, reduce feed ratio by 10%, and cut losses by 50%, achieving "reduced protein without compromising nutrition" [1] Group 3: Implementation and Results - A comprehensive support system has been established, including professional procurement teams, expert-led production processes, and a feedback mechanism involving all staff to gather practical data from aquaculture sites [2] - The strategy has been successfully applied to various species, resulting in lower protein levels than industry standards, improved stability in high-temperature and high-density farming scenarios, reduced disease incidence, and better water quality [2] Group 4: Future Directions - The company aims to leverage the summit to share technical experiences and product systems, collaborating with industry partners to enhance raw material optimization, formula iteration, and service upgrades [2] - The goal is to help the aquaculture industry overcome resource constraints and progress towards a high-quality development phase characterized by precision, efficiency, and environmental sustainability [2]

公告显示，截至2025年11月30日，公司"年产120吨原料药建设项目"募集资金计划投资2.64亿元，募集 资金账户已累计投入1.36亿元。"智能化特色原料药配套产业链项目"募集资金计划投资1亿元，募集资 金账户已累计投入3675.90万元。 中证报中证网讯(王珞)12月8日晚，新天地（301277）发布公告称，公司于2025年12月6日召开第六届董 事会第九次会议和第六届监事会第九次会议，审议通过《关于募集资金投资项目结项并将节余募集资金 永久补充流动资金及注销募集资金专户的议案》。公司首次公开发行股票募集资金投资项目"年产120吨 原料药建设项目"和使用首次公开发行股票超募资金投资建设的"智能化特色原料药配套产业链项目"已 达到预定可使用状态，公司拟将上述项目进行结项，并将节余募集资金(含利息收入及现金管理收益 等，具体金额以资金转出当日募集资金专户余额为准)用于永久补充流动资金并注销募集资金专户。 新天地表示，本次"年产120吨原料药建设项目"和"智能化特色原料药配套产业链项目"结项并将节余募 集资金永久补充流动资金，有助于满足公司日常生产经营对流动资金的需求，可以提高公司经营效率， 符合公司及全体股东 ...

截至公告日，潘峰持有郑州银行1331股A股股份。 公告显示，潘峰，1971年7月出生，本科学历。1993年7月加入郑州银行，历任总行办公室职员、办公室 副主任(主持工作)、办公室主任、董事会办公室办公室秘书、董事会办公室主任、董事会风险管理办公 室主任、新密郑银村镇银行股份有限公司董事长，现任郑州银行首席风险官、总行董事会战略发展部总 经理兼关联交易管理中心主任。 中证报中证网讯(王珞)12月8日晚，郑州银行（002936）发布公告称，该行于近日收到国家金融监督管 理总局河南监管局下发的《河南金融监管局关于潘峰郑州银行股份有限公司首席风险官任职资格的批 复》，核准潘峰的该行首席风险官的任职资格。 ...

Group 1 - Shenzhen Xinsong Semiconductor Co., Ltd. successfully completed a C-round financing of 269 million yuan, attracting strategic investments of 249 million yuan from leading automotive PCB company Shiyun Circuit and its affiliates, along with an additional 20 million yuan from existing shareholder Hongsheng Capital [1] - Xinsong Semiconductor specializes in the filter field, having established a stable supply chain for well-known brands such as Xiaomi, Honor, Samsung, and Motorola, and is the first domestic filter company to pass AEC-Q200 automotive certification, achieving mass production of several automotive-grade filters [1] - Shiyun Circuit is a leading player in the automotive PCB sector, serving major global electric vehicle brands like Tesla, BMW, and Mercedes-Benz, and acts as a crucial link in the supply chain between components and vehicle manufacturers [1] Group 2 - Leveraging Shiyun Circuit's industry resources, the financing is expected to accelerate the entry of Xinsong Semiconductor's automotive-grade filters into the front-loading market, significantly shortening the cycle from certification to mass supply and enhancing service capabilities for domestic ODM manufacturers and consumer electronics clients [2] - The strategic investment will enable both companies to develop integrated solutions combining PCB and filters, focusing on new modular products tailored to smart vehicle demands, thereby strengthening their competitive advantage in the automotive PCB sector and expanding business growth opportunities [2]

中证报中证网讯(王珞)近日，马来西亚首都吉隆坡迎来一场中医药国际交流盛会——"脑心同治理论与 实践国际研讨会暨国际脑心同治协会马来西亚分会成立大会"。来自中国、马来西亚、新加坡三国的两 百余名中西医医师齐聚一堂，共话健康福祉。 中国中西医结合学会脑心同治专业委员会主任委员赵超在大会上系统阐释了脑心同治理论的发展脉络与 核心价值：该理论由赵步长教授、伍海勤教授及赵涛博士共同提出，突破传统诊疗思维，将心脑两系视 为有机整体，强调从整体出发调和脏腑、平衡气血，为心脑血管疾病防治开辟了全新路径。经过数十年 的文献研究、实验验证与临床积累，这一理论已形成兼具科学性与先进性的创新体系，并被编入国家卫 生健康委员会"十三五"规划教材。此外，为推动理论落地，脑心同治专委会联合王永炎院士、张伯礼院 士等顶尖专家及科研机构成立脑心同治研究院，聚力攻克科研难题、推动成果转化；目前中国各省及地 级城市均已建立脑心同治学会，形成上下联动的发展格局；国际层面已相继成立印尼、加纳、哈萨克斯 坦等海外分会及中国香港地区分会，为全球医师学者搭建起常态化学术交流平台。 在全场嘉宾的共同见证下，大会举行了马来西亚脑心同治分会授牌仪式与脑心同治人才 ...

Core Viewpoint - The construction materials industry is undergoing significant transformation driven by innovation and green initiatives, aiming for high-quality development during the 14th Five-Year Plan period [1][3]. Group 1: Industry Development - The construction materials industry is experiencing a structural upgrade with the emergence of "new three types" of materials: green building materials, photovoltaic glass, and fiberglass composite materials [1][3]. - The industry has seen a 36.9% increase in the number of large-scale enterprises and a 54.2% growth in total assets [3]. - Revenue from green building materials has surpassed 205 billion, with an annual growth rate of 20% [3]. Group 2: Environmental Impact - The construction materials industry has achieved a 20.4% cumulative reduction in carbon dioxide emissions over the past four years [3]. - The industry is focusing on low-carbon transformation and digitalization, with a projected 66.5% automation rate in key processes by 2024 [3]. Group 3: Collaboration and Integration - There is a strong emphasis on deepening collaboration between the construction materials and construction industries to create a new development pattern [2]. - The industry aims to establish effective communication and feedback mechanisms to align material applications with construction needs [2]. Group 4: Future Directions - The construction materials industry is urged to adopt a global perspective to drive systemic changes and explore new development pathways focused on high-quality growth [3]. - The China Building Materials Federation plans to enhance research on "good materials" and promote their integration into the construction sector [4].